MENU

Tricor

Tricor

 

 



































The effect of Tricor on coronary heart problem morbidity as well as mortality and also non-cardiovascular mortality has not been set up.



The Action to Control Cardiovascular Risk in Diabetes Lipid (ACCORD Lipid) trial was a randomized placebo-controlled study of 5518 patients with type 2 diabetic issues mellitus on background statin therapy treated with fenofibrate. The mean duration of follow-up was 4.7 years. Fenofibrate plus statin mix treatment showed a non-significant 8 % family member danger reduction in the primary end result of major unfavorable cardio occasions (MACE), a composite of non-fatal myocardial infarction, non-fatal stroke, and also heart attack death (threat ratio [Human Resources] 0.92, 95 % CI 0.79-1.08) (p=0.32) as compared with statin monotherapy. In a gender subgroup evaluation, the hazard proportion for MACE in males receiving combination treatment versus statin monotherapy was 0.82 (95 % CI 0.69-0.99), and also the hazard proportion for MACE in ladies obtaining mix therapy versus statin monotherapy was 1.38 (95 % CI 0.98-1.94) (interaction p=0.01). The clinical relevance of this subgroup searching for is unclear.



The Fenofibrate Intervention and also Event Lowering in Diabetes (FIELD) research was a 5-year randomized, placebo-controlled study of 9795 individuals with type 2 diabetic issues mellitus treated with fenofibrate. Fenofibrate showed a non-significant 11 % relative decrease in the main outcome of coronary heart problem occasions (danger proportion [HR] 0.89, 95 % CI 0.75-1.05, p=0.16) and a significant 11 % decrease in the secondary result of total heart attack events (HR 0.89 [0.80-0.99], p=0.04). There was a non-significant 11 % (HR 1.11 [0.95, 1.29], p=0.18) and 19 % (HR 1.19 [0.90, 1.57], p=0.22) rise in coronary and complete heart condition mortality, specifically, regarding fenofibrate as contrasted to placebo.

All rights reserved (c) 2011